Viking Therapeutics (VKTX.O) is seeing renewed investor interest as the company advances its obesity drug pipeline, with analysts projecting a potential 150% upside for the stock.
The biotech firm is currently testing a new active ingredient while simultaneously preparing for a critical data readout from another key study in the third quarter.
The market reaction reflects the high stakes attached to the upcoming clinical milestones.
A positive outcome from the third-quarter trial results could serve as a major catalyst, potentially driving a sharp re-rating of the shares.
Investors are closely monitoring the progress of the new compound, which represents a significant addition to the company's portfolio beyond its existing lead candidates.
The obesity treatment sector remains one of the most competitive and high-growth areas in biotechnology.